Cover Image
市場調查報告書

Lead Discovery Center GmbH:產品平台分析

Lead Discovery Center GmbH - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 319983
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
Lead Discovery Center GmbH:產品平台分析 Lead Discovery Center GmbH - Product Pipeline Review - 2016
出版日期: 2016年07月27日 內容資訊: 英文 76 Pages
簡介

Lead Discovery Center GmbH 是正在開發針對癌症及發炎性疾病、神經退化循環系統疾病、代謝症候群、傳染病、未滿足的臨床需求等重大症狀所用的藥劑及治療法之生物醫學研究企業。該公司也透過產學聯合研究開發中。

本報告提供Lead Discovery Center GmbH的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Lead Discovery Center GmbH的基本資料

  • Lead Discovery Center GmbH概要
  • 主要資訊
  • 企業資料

Lead Discovery Center GmbH :R&D概要

  • 主要的治療範圍

Lead Discovery Center GmbH :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Lead Discovery Center GmbH :開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Lead Discovery Center GmbH :藥物簡介

  • LDC-2636
  • LDC-4297
  • Small Molecules for Oncology
  • Small Molecule 1 For Cancer
  • Small Molecule 2 for Cancer
  • Small Molecule for Amyotrophic Lateral Sclerosis
  • Small Molecule for Cancer
  • Small Molecule for Cancer, Inflammation and AMD
  • Small Molecule to Activate TRIM32 for Neurodegenerative Disease
  • Small Molecule to Inhibit AML1/ETO for Acute Myeloid Leukemia
  • Small Molecule to Inhibit Chemerin for Inflammation
  • Small Molecule to Inhibit degS Serine Endoprotease for Bacterial Infections
  • Small Molecule to Inhibit HIF1A for Cancer and Metabolic Syndrome
  • Small Molecule to Inhibit Immunoproteasome Subunit LMP7 for Autoimmune Disorder and Viral Infections
  • Small Molecule to Inhibit LRRK2 for Parkinson's Disease
  • Small Molecule to Inhibit SFRP1 for Cancer
  • Small Molecule to Target FKBP51 for Major Depressive Disorder
  • Small Molecule to Target Hedgehog Pathway for Oncology
  • Small Molecule to Target K-Ras/PDE Delta for Cancer
  • Small Molecule to Target MARK2 for Alzheimer's Disease
  • Small Molecule to Target Nrg1-ErbB4 Pathway for Schizophrenia
  • Small Molecule to Target Plexin-B1/Sema4D for Multiple Sclerosis and Osteoporosis
  • Small Molecule to Target Rab-1 for Solid Tumors
  • Small Molecule to Target SLC6A15 for Major Depressive Disorder
  • Small Molecule-3 for Cancer
  • Small Molecules for Atherosclerosis and Obesity
  • Small Molecules for Cancer
  • Small Molecules for Influenza
  • Small Molecules for Lung Cancer
  • Small Molecules to Activate SIRT for Metabolic Syndrome and Cardiovacular Diseases
  • Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Immunology and Infectious Diseases
  • Small Molecules to Inhibit Cyclophilin for Immunology and Respiratory Disorders
  • Small Molecules to Inhibit NET Formation for Sepsis and SLE
  • Small Molecules to Target Notch Signaling Pathway for Oncology

Lead Discovery Center GmbH :開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Lead Discovery Center GmbH :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08100CDB

Summary

Global Markets Direct's, 'Lead Discovery Center GmbH - Product Pipeline Review, 2016', provides an overview of the Lead Discovery Center GmbH's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Lead Discovery Center GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Lead Discovery Center GmbH
  • The report provides overview of Lead Discovery Center GmbH including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Lead Discovery Center GmbH's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Lead Discovery Center GmbH's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Lead Discovery Center GmbH's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Lead Discovery Center GmbH
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lead Discovery Center GmbH's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Lead Discovery Center GmbH Snapshot
    • Lead Discovery Center GmbH Overview
    • Key Information
    • Key Facts
  • Lead Discovery Center GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • Lead Discovery Center GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Lead Discovery Center GmbH - Pipeline Products Glance
    • Lead Discovery Center GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Lead Discovery Center GmbH - Drug Profiles
    • Small Molecule for Target RhoGEF12 for Cardiovascular Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Activate Beclin1 for Neurodegenerative Diseases and Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit FKBP51 for Anxiety and Major Depressive Disorder
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize RON Kinase for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Cyclophilin for Immunology and Respiratory Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • englerin A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 3 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 4 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for AMD, Inflammation and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Amyotrophic Lateral Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Chlamydia Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small molecule for Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Activate TRIM32 for Neurodegenerative Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize P2Y6R for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Block TRPC4 and TRPC5 for Cardiovascular Disease and Epilepsy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit AML1/ETO for Acute Myeloid Leukemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK12 and CDK13 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Chemerin for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit degS Serine Endoprotease for Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit GLUT1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit GRK5 for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit MARK2 for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Plexin-B1/Sema4D for Multiple Sclerosis and Osteoporosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit RabGGTase for Solid Tumors
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit SFRP1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Steroid Sulfatase for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Target Draxin for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Target Hedgehog Pathway for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Target K-Ras/PDE Delta for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Target Nrg1-ErbB4 Pathway for Schizophrenia and Cardiovascular Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Target SLC6A15 for Major Depressive Disorder
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules 1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Charcot-Marie-Tooth Disease Type I A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Influenza
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Lung Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate GFAT for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize GPR81 for Atherosclerosis and Obesity
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit LRRK2 for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit NET Formation for Sepsis and SLE
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Target Notch Signaling Pathway for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Target SIRT7 for Cardiovacular Diseases, Metabolic Syndrome and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lead Discovery Center GmbH - Pipeline Analysis
  • Lead Discovery Center GmbH - Pipeline Products by Target
  • Lead Discovery Center GmbH - Pipeline Products by Molecule Type
  • Lead Discovery Center GmbH - Pipeline Products by Mechanism of Action
  • Lead Discovery Center GmbH - Recent Pipeline Updates
  • Lead Discovery Center GmbH - Dormant Projects
  • Lead Discovery Center GmbH - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Lead Discovery Center GmbH, Key Information
  • Lead Discovery Center GmbH, Key Facts
  • Lead Discovery Center GmbH - Pipeline by Indication, 2016
  • Lead Discovery Center GmbH - Pipeline by Stage of Development, 2016
  • Lead Discovery Center GmbH - Monotherapy Products in Pipeline, 2016
  • Lead Discovery Center GmbH - Partnered Products in Pipeline, 2016
  • Lead Discovery Center GmbH - Partnered Products/ Combination Treatment Modalities, 2016
  • Lead Discovery Center GmbH - Out-Licensed Products in Pipeline, 2016
  • Lead Discovery Center GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Lead Discovery Center GmbH - Preclinical, 2016
  • Lead Discovery Center GmbH - Discovery, 2016
  • Lead Discovery Center GmbH - Pipeline by Target, 2016
  • Lead Discovery Center GmbH - Pipeline by Molecule Type, 2016
  • Lead Discovery Center GmbH - Pipeline Products by Mechanism of Action, 2016
  • Lead Discovery Center GmbH - Recent Pipeline Updates, 2016
  • Lead Discovery Center GmbH - Dormant Developmental Projects,2016

List of Figures

  • Lead Discovery Center GmbH - Pipeline by Top 10 Indication, 2016
  • Lead Discovery Center GmbH - Pipeline by Stage of Development, 2016
  • Lead Discovery Center GmbH - Monotherapy Products in Pipeline, 2016
  • Lead Discovery Center GmbH - Partnered Products in Pipeline, 2016
  • Lead Discovery Center GmbH - Out-Licensed Products in Pipeline, 2016
  • Lead Discovery Center GmbH - Pipeline by Top 10 Target, 2016
  • Lead Discovery Center GmbH - Pipeline by Molecule Type, 2016
  • Lead Discovery Center GmbH - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top